It treats that distinction as one part of a structured clinical assessment rather than a diagnosis
[Google Scholar] 47.Sink B., Garrigues T.M., Balogh G.T., Nagy Z.K., Tsinman O., Avdeef A., Takcs-Novk K
GLP-1 agonists overall were associated with a 3.67 times higher risk of developing gastroparesis compared to non-users, but within that elevated risk category, tirzepatide appears significantly safer than semaglutide
Alongside this, GSTT1 also contributes to detoxification of reactive oxygen species derived products and some environmental and occupational chemicals
This makes it especially relevant for age-related diseases like cardiovascular disease, neurodegeneration and metabolic disorders where chronic inflammation is a central driver
FA fatty acids